Abstract
Dear Editor,
We found the article “Effect of COVID vaccination on monthly migraine days: A longitudinal cohort study” (1) interesting. During the COVID-19 epidemic, 547 migraine patients kept an E-diary of their headaches. A questionnaire was emailed to them in order for them to record their COVID-19 infection and/or immunization dates. Following the application of inclusion criteria, 59 people were included in the infection analysis and 147 participants in the vaccination analysis. The change in monthly migraine days (MMD) between one month before and one month after COVID-19 infection or vaccination was the primary outcome monitored. Changes in monthly headache days (MHD) and monthly acute medication days (MAMD) were secondary outcome variables.
The study’s weakness is its small sample size, which restricts the findings’ generalizability and statistical power. The infection analysis comprised 59 subjects, and the vaccine analysis included 147 persons. This small sample size may not effectively represent the greater population of migraine patients, and the results may not be generalizable. Furthermore, the study relied on self-reported data from participants, which raises the possibility of recollection bias and reporting mistakes. The stated COVID-19 infection and vaccination dates could have an impact on the outcomes and interpretation of the findings. Furthermore, while the study’s primary outcome was the change in monthly migraine days (MMD), it did not analyze potential underlying mechanisms or explore other important variables that could contribute to changes in migraine symptoms post-infection or post-vaccination. A more extensive review of factors such as stress levels, lifestyle changes, or medication adjustments that may have influenced the observed changes in migraine symptoms would have improved the study.
A clinical manifestation of asymptomatic COVID-19 may occur at any moment, including before, during, or after catching the virus, receiving the COVID-19 immunization, or at any other time. Even in the absence of obvious symptoms, COVID-19 can co-occur (2). Asymptomatic sickness cannot be totally ruled out without the required laboratory tests. Genetics are used more and more frequently, and, depending on how the immune system responds to particular genetic traits, the immune system’s response to a vaccine may vary. Larger sample sizes and more multicenter trials are desirable. This may be preferable for in-depth epidemiological studies on the connections between illness and immunization.